This updated integrated safety analysis evaluated oral ritlecitinib (JAK3/TEC family kinase inhibitor) across 4 ALLEGRO clinical trials in patients aged ≥12 years with alopecia areata (AA), pooling data up to ~5 years of exposure (primary group: ritlecitinib 50 mg ± 200 mg loading dose, N=1,228; any-ritlecitinib group, N=1,294).
Over a median exposure of ~1,200 days, serious AEs occurred in 6.8% of patients (2.5–2.6/100 PYs); AE-related discontinuation was ~8–8.4%. Key safety signals were low: herpes zoster IR 1.0/100 PYs, opportunistic infections 0.1/100 PYs, malignancies (excluding NMSC) 0.3/100 PYs, and major adverse cardiovascular events 0.2/100 PYs. There were 2 deaths across both groups.
- No placebo or active comparator arm for long-term safety benchmarking; descriptive analysis only. - Pooled design includes multiple dose levels and loading-dose variations, limiting dose-specific conclusions. - Open-label extension data dominate the longer follow-up, which may introduce selection bias toward tolerators.
Ritlecitinib 50 mg appears well tolerated over ~5 years in adolescents and adults with AA, with low rates of serious infections, malignancy, and cardiovascular events comparable to earlier reports. Clinicians can be reassured by the consistent long-term safety profile, though ongoing monitoring for herpes zoster (IR 1.0/100 PYs) remains prudent.
Explore related topics
